Chi-Med Starts China Phase I Trial of Syk Inhibitor
January 11, 2017 at 05:23 AM EST
Hutchison China MediTech (Chi-Med) has begun treating cancer patients in a China Phase I trial of HMPL-523, a novel spleen tyrosine kinase (Syk) inhibitor. The patients have hematological malignancies, including lymphoma and leukemia. In November of last year, Chi-Med reported that an Australian trial of HMPL-523 for arthritis showed a dose-dependent suppression of B-cell activation, with lower rates of diarrhea and hypertension than first-generation Syk inhibitors. More details.... Stock Symbols: (NSDQ/AIM: HCM) Share this with colleagues: // //